Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia
| Autor: | Daishi Onai, Atsushi Marumo, Shunsuke Yui, Masahiro Sakaguchi, Satoshi Yamanaka, Hayato Tamai, Satoshi Wakita, Hiroki Yamaguchi, Kazuki Inai, Tomoaki Kitano, Kazuki Terada, Kenji Tajika, Kazutaka Nakayama, Taichiro Tokura, Yusuke Fujiwara, Masahiro Okabe, Muneo Okamoto, Ikuko Omori, Shun Nakagome, Kunihito Arai, Koiti Inokuchi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Multivariate analysis Adolescent Clinical Biochemistry 030204 cardiovascular system & hematology Gene mutation medicine.disease_cause Disease-Free Survival 03 medical and health sciences Myelogenous 0302 clinical medicine Internal medicine medicine Humans Aged Aged 80 and over Mutation Performance status business.industry Incidence (epidemiology) Remission Induction Biochemistry (medical) Hematology General Medicine Middle Aged medicine.disease Neoplasm Proteins Survival Rate PTPN11 Leukemia Myeloid Acute Leukemia Female business 030215 immunology |
| Zdroj: | International Journal of Laboratory Hematology. |
| ISSN: | 1751-553X 1751-5521 |
| Popis: | INTRODUCTION Acute myelogenous leukemia (AML) in elderly patients is associated with an increased incidence of complications and treatment-related toxicity because of the frequency of comorbid disease and age-related deterioration in organ function. Despite advances in AML treatment in recent years, elderly patients have experienced limited benefit, and their outcomes remain poor. This study aimed to perform a comprehensive gene mutation analysis in elderly AML patients and identify gene mutations that could serve as prognostic factors. METHODS An analysis of gene mutations was performed for 281 AML patients, including 98 elderly patients aged 65 years or above. RESULTS Compared to younger AML patients, elderly patients showed a higher frequency of the following gene mutations: TP53 (P = 0.026), PTPN11 (P = 0.006), RUNX1 (P = 0.024), TET2 (P = 0.002), and ASXL1 (P = 0.023). The complete remission rate was significantly lower in DNMT3A mutation-positive cases (4.26%, P = 0.011) and TP53 mutation-positive cases (2.13%, P = 0.031) than in negative cases. The overall survival rate was significantly poorer in cases with FLT3-ITD (P = 0.003), DNMT3A (P = 0.033), or TP53 mutation (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text